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1040-67 The Impact of the National Privacy Act on the 
Effectiveness and Costs of a Six-Month Follow-Up 
Study of Acute Coronary Syndromes
David Armstrong, Eva M. Kline-Rogers, Jianming Fang, Anchal Sud, Krishna Rangarjan, 
Shaneen U. Doctor, Bruce C. Rogers, Debra Smith, Kim A. Eagle, University of Michigan, 
Ann Arbor, MI
Objective: To determine the potential impact of the new privacy act (HIPAA) on post dis-
charge outcomes (effectiveness and costs) in patients with Acute Coronary Syndromes
(ACS).
Methods: We studied follow-up(F/U) success at 6 months, and costs of F/U in two
cohorts of consecutive discharges with ACS between 5-1-99 and 4-24-03 at the Univer-
sity of Michigan Health System. The first interval represented usual outcomes assess-
ment, with 6 month phone interviews which first sought verbal consent from patients,
then proceeded with a brief questionnaire. In the second interval, using methodology rec-
ommended by our IRB as being HIPAA compliant, we first mailed a consent to each dis-
charged patient, asking permission to call the patient in order to add their clinical data to
a database and obtain F/U information. We tracked overall success of consent for 6
month F/U, incremental costs of securing F/U, including estimated materials, mailing,
phone, personnel costs, and assessed for differences in types of patients successfully
consented.
Results: Overall consent for F/U dropped from 96.5 % to 35.9% after initiation of HIPAA
compliant procedures, p<.0001. Per patient costs increased by an estimated $17.00.
More than one half of patients did not reply to the consent letter. After receiving the letter,
2.6% of patients refused to be contacted and 1.5% of letters were "returned to sender".
Patients successfully consented for F/U after HIPAA were more likely to be married
(p<.0001), were older (p=.001) and have a history of hypertension (p=.004) or hyperlipi-
demia (p=.04) versus those that did not respond, refused, or never received the letter.
Widowers were less likely to respond (p<.0001). There were no differences with regard to
gender, or other comorbid conditions between those that did or did not consent.
Conclusions: Adjusting outcomes research methodology to accomodate new regulations
associated with HIPAA resulted in substantial reduction in our ability to successfully track
care patterns and outcomes in pts discharged after admission for ACS, and was associ-
ated with greater costs. This pilot study suggests that HIPAA may significantly alter the
way we study long term patient outcomes in cardiology.
1040-68 Excessive Inducement Into Clinical Trials Using 
Monetary Incentives: Truth or Fallacy?
Joel B. Braunstein, Steven P. Schulman, Parthiv Mahadevia, Neil R. Powe, Johns 
Hopkins Medical Institutions, Baltimore, MD
Background: While use of monetary incentives to enhance recruitment into clinical trials
is controversial, scant empiric data exist on how monetary incentives actually influence
patients’ enrollment decisions. Thus, we asked whether and to what degree monetary
incentives influence patients’ willingness to participate (WTP) in a cardiovascular clinical
trial.
Methods: From 13 Maryland-based cardiology and medicine clinics, we approached
1440 randomly selected patients to participate in a cross-sectional, self-administered
survey, which contained a 1-page description of a cardiovascular drug trial with random
assignment of a different level of monetary incentive. Monetary incentive for joining ran-
domly varied between $25, $250, $500, $750, and $1250. Using 5-point Likert response
scaling, patients reported their WTP ([+] response = very likely/ likely), and their rated
importance of joining a trial for altruistic reasons and for receiving monetary incentive.
Results: 789 (70%) of 1132 eligible individuals responded. Magnitude of monetary
incentive had no impact on WTP (WTP=32%, 36%, 34%, 33%, 38% for $25, $250, $500,
$750 and $1250 incentive, respectively, p=0.80), even after stratifying individuals by
socioeconomic status, age, gender, and race. Individuals who considered monetary
incentive important to join a trial, however, expressed greater WTP (OR=1.24; 95% CI
1.11-1.38, p<0.001 per ordered increase in importance), as did individuals who consid-
ered it important to join a trial to help other people (2.32; 1.92-2.81, p<0.001 per ordered
increase in importance). Lower income and education levels were both strongly and inde-
pendently associated (1.33; 1.08-1.63, p<0.01 and 1.65; 1.26-2.16, p<0.001 per ordered
decrease in income and education, respectively) with reports of monetary incentive being
either extremely or very important to joining a trial. All subgroups felt similarly about the
importance of joining a trial to help other people.
Conclusions: Monetary incentives did not adversely influence WTP in this hypothetical
experiment, although, persons with lower income and education were more likely to
believe that monetary incentives are important for joining trials.
1040-69 The Effect of State Mandated Continuing Medical 
Education on the Use of Proven Therapies in Patients 
With an Acute Myocardial Infarction
Manesh R. Patel, Trip J. Meine, Jasmina Radeva, Lesley Curtis, Sunil V. Rao, Kevin J. 
Schulman, James Jollis, Duke University Medical Center, Durham, NC
Background: Many states mandate continuing medical education (CME) credits for
practicing physicians. We examined whether state CME requirements affected the use of
evidence-based therapies and outcomes in patients with acute myocardial infarction
(AMI).
Methods: We analyzed 134,609 patients in a Medicare database admitted with the diag-
nosis of AMI to US hospitals from 1994-1996 according to CME requirements in the state
of physician practice. We used a hierarchical multivariable model controlling for state,
hospital, physician, and patient characteristics to determine the association between
state CME requirements and the use of evidence-based therapies.
Results: States with and without CME requirements had similar rates of aspirin use at
admission and discharge and beta blocker use at discharge. The rate of reperfusion ther-
apy at admission was significantly higher in states requiring CME.(Table) After adjust-
ment, patients admitted in states requiring CME were significantly more likely to receive
reperfusion therapy, mainly due to thrombolytic therapy (RR 1.08 p=0.023). There was no
association between CME requirements and 30-day or 1-year mortality.
Conclusion: State-mandated CME training had little association with AMI care or out-
come, other than an increased use of thrombolytic therapy. Further study is needed to
determine whether the association with thrombolysis was related to the provision of CME
activities in conjunction with pharmaceutical marketing efforts.
1040-70 Do International Medical Graduates Provide Inferior 
Quality Care in the Setting of Acute Myocardial 
Infarction?
Dennis T. Ko, Peter C. Austin, Benjamin T.B. Chan, Jack V. Tu, Sunnybrook and Women’s 
College Health Sciences Center, Toronto, ON, Canada, Institute for Clinical Evaluative 
Sciences, Toronto, ON, Canada
Background
International medical graduates (IMGs) represent a substantial proportion of the physi-
cian workforce and are important in the care of AMI patients. Although not firmly estab-
lished, many believe that IMGs provide inferior medical care compared to locally trained
physicians.
Methods 
We compared risk-adjusted mortality rates, adjusted use of secondary prevention medi-
cations and cardiac procedures of patients treated by IMGs and Canadian Medical grad-
uates (CMGs) using linked administrative databases for all patients admitted with AMI
between 1992 and 1999 in Ontario, Canada.
Results
Of the 127,275 AMI patients, 22% were treated by IMGs, and 78% by CMGs. IMGs were
older (51 vs 40 yrs) and more likely to be male (90% vs 72%) compared to CMGs. The
risk-adjusted mortality rates of IMG and CMG-treated patients were similar both at 30-
day (13.3% vs 13.4%, p = 0.57) and at 1-year (21.8% vs 21.9%, p = 0.63). Further,
patients treated by both groups had similar adjusted utilization of secondary prevention
medications and cardiac procedures.
Conclusions
Despite concerns about a lower level of care provided by IMGs, the utilization of second-
ary prevention medical therapy, cardiac procedures, and mortality of AMI patients was
similar after adjustment. This information places the concerns about IMGs into perspec-
tive and supports the ability of well-selected IMGs in caring for AMI patients. 
Use of Evidence-Based Therapy in AMI
States with no CME-
requirement N=63,299
CME-requiring 
States N=71,310
P-Value
Aspirin:
During 79.4% 79.9% 0.088
at discharge 72.5% 72.5% 0.947
Beta-Blocker use
 During 63.3% 61.6% 0.045
 Discharge 55.3% 53.1% 0.068
Reperfusion at 
Admission
 PCI 18.6% 20.9% 0.0007
Thrombolytic 42.6% 47.2% <0.0001
Mortality
 30-day 20.5% 20.7% 0.467
 1-year 35.2% 35.0 0.564
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1040-71 Interhospital Transfers Are Costly, Cause Delays and Do 
Not Address the Imbalance of Access to 
Revascularization: The Case for More Angiographic 
Facilities? Results From the Global Registry of Acute 
Coronary Events
Ameet Bakhai, Omar H. Dabbous, David J. Cohen, Marcus D. Flather, Dan Greenberg, 
Frederick A. Anderson, Jr., Enrique P. Gurfinkel, Kami White, Keith A.A Fox, The GRACE 
Investigators, Royal Brompton Hospital, London, United Kingdom
Background Hospital revascularization rates for patients (pts) admitted with acute coro-
nary syndromes (ACS) vary depending on proximity to a hospital capable of coronary
revascularization. We examined whether interhospital transfers balance out these varia-
tions and represent the most effective use of resources.
Methods We compared clinical outcomes, resource use and costs for ACS pts enrolled
in GRACE to Dec ’02, presenting directly to centers with (Rv+) or without (Rv-) 24h
access to revasc (PCI/CABG) facilities and for pts transferred (Tr) to a Rv+ unit for acute
care. Costs were estimated ($/€) using key drivers: length of stay, ward type and use of
PCI, stent or CABG.
Results 25,344 pts presented initially to Rv+ (74%) and Rv- (26%). Almost 1 in 5 pts
needed acute Tr. Overall hospital mortality rates were similar (5.4%) for Rv+ and Rv- pts.
Mean cost of all ACS pts was $6001/€5253. Almost 1 in 3 Tr pts did not proceed to
revasc. In the UK alone, the estimated cost of care of Tr pts annually would be $50(€42)
million.
Conclusions Tr rates would have to increase from 20% to 60% to balance the substan-
tial differences in revasc rates between centers. Access to angiography before Tr would
realise substantial potential cost savings by avoiding Tr for pts unlikely to proceed to
revasc. Further economic data is urgently needed to determine the most optimal use of
resources. Increased angiographic facilities may also allow more equitable access to
early revasc for all ACS pts with suitable anatomy.
1040-72 Are American College of Cardiology/American Heart 
Association Preoperative Practice Guidelines for Stress 
Testing Followed?
Howard Weinstein, Barbara Spaltro, Richard M. Steingart, Memorial Sloan-Kettering 
Cancer Center, New York, NY
Background: ACC/AHA preoperative practice guidelines for stress testing are widely
promulgated but the extent to which they are followed and applicable in specialized popu-
lations is unknown.
Methods: Accordingly, we retrospectively applied the ACC/AHA preoperative guidelines
to a group of 776 consecutive patients (pts) undergoing abdominal, genitourinary, head
and neck or thoracic cancer surgery referred for preoperative exercise stress echocardio-
graphy (ESE).
Results: Eighty-four percent of stress tests were not indicated by existing ACC/AHA
guidelines. The rate of cardiac events (AMI, CHF, UA and death ) in these pts was low
(1.8%) and ESE provided no further risk stratification (Fig). In pts where stress testing
was indicated by the guidelines, the event rate was 7%. ESE provided further risk stratifi-
cation in this group (Fig).
Conclusions: 1) Compliance with preoperative stress testing guidelines in this popula-
tion is poor, resulting in extensive testing that provides no further risk stratification. 2)
Where stress testing is indicated by guidelines, ESE provides important prognostic infor-
mation.
1040-73 Financial Impact of Drug-Eluting Stents: The US 
Academic Experience
David S. Marks, Thomas A. Ratko, Karl A. Matuszewski, Michael J. Oinonen, Joseph P. 
Cummings, Medical College of Wisconsin, Milwaukee, WI, University HealthSystem 
Consortium, Oak Brook, IL
Background: Drug-eluting stents (DES) have recently been released in the United States
in limited quantity. These stents have changed the financial impact of coronary interven-
tion. The impact of DES in the initial US rollout has not been described.
Methods: The University HealthSystem Consortium (UHC) is an alliance of 87 academic
health centers in the US. The UHC clinical database was queried for DES implantation
compared to bare stent implantation for the second quarter (Q2) of 2003. This database
contains a comprehensive collection of procedure-specific data derived from discharge
abstract summaries and UB-92 data for all inpatients at participating centers.
Results: 11,866 procedures involving coronary stents from 74 institutions performed in
Q2 were analyzed, including 3,404 procedures using DES. Penetration of DES increased
monthly and reached 44% by June, 2003. Mean length of stay was lower for DES proce-
dures compared to bare stent procedures both with myocardial infarction (MI) (3.51±2.84
vs. 3.98±3.47 days, p<0.01) and without MI (1.99±2.29 vs.2.39±2.98, p<0.01). Overall
procedural costs increased for DES both with myocardial infarction ($18,150±9,900 vs.
$17,225±10,500) and without ($13,400±8,200 vs. $14,953±8,200). No difference existed
in payer status or clinical demographics between bare stents and DES.
Conclusion: The introduction of DES has increased costs to health care centers and the
technology has had rapid adoption despite limited supply. Yet, retrospective database
analysis suggests the cost of caring for patients with DES has risen by a quantity less
than the incremental price of a single stent; this may be explained, in part, by a
decreased LOS. No patient clinical or demographic criteria attesting to this savings has
been ascertained by a comprehensive clinical database. Further investigation is required
to understand the patient and physician characteristics that have determined DES utiliza-
tion and non-stent cost savings.
1040-74 Drug-Eluting Stent Use May Negatively Impact the 
Economic Health of a Hospital: A Single-Center Case 
Study
Richard E. Sinaiko, Mikele M. Bunce, Neal Eigler, Saibal Kar, Sepideh S. Farivar, Emma 
C. Wollschlager, Sinaiko Healthcare Consulting, Inc., Los Angeles, CA, Cedars-Sinai 
Health System, Los Angeles, CA
Background: Drug eluting stents (DES) are becoming the "gold standard" for treatment
of coronary artery disease due to decreased rates of restenosis. The economic implica-
tions of this costly technology may be greater than expected. This study was conducted
to forecast the financial impact of DES use on a major teaching hospital.
Methods: A case study hospital’s caseload, cost, and reimbursement data were used to
perform a sensitivity analysis using a financial impact model developed by Cordis, which
was run using two different sets of assumptions: (1) Cordis’ assumptions, and (2) case
study hospital’s assumptions. The case study hospital's assumptions were obtained by
surveying a group of the hospital’s interventional cardiologists.
Results: The results of this study (Figure 1) show that while Cordis’ assumptions show
less of an impact, under both Cordis’ and the case study’s assumptions, the case study
hospital will undergo a significant reduction in cardiovascular service line contribution
margin as a result of drug eluting stent use.
Conclusions: Hospitals have little control over the financial impact of DES due to
demand, liability, and guideline enforcement issues. To relieve the burden hospitals face
and to ensure the healthcare community has appropriate incentives to practice in a cost-
effective and patient centered way, Medicare should increase its reimbursement rates for
IMGs CMGs Adjusted Odds 
Ratio IMGs/CMGs 
(95% CI)
Medications within 90 days of hospital 
discharge, (%)
Aspirin 61.4 60.4 1.00 (0.94, 1.06)
Beta Blockers 53.8 56.4 1.01 (0.94, 1.07)
ACE inhibitors 51.3 52.0 1.04 (0.98, 1.11)
Statins 19.1 19.8 1.09 (1.01, 1.19)
Cardiac Procedures within 1 year of hospital 
discharge, (%)
Cardiac Catheterizations 31.0 32.6 1.06 (1.01, 1.18)
PCI 9.1 9.9 1.06 (1.00, 1.13)
CABG 9.6 10.3 1.00 (0.95, 1.06)
Category Admitted to 
Rev+ (n=18,817)
Admitted to 
Rev- (n=6527)
Transferred to 
Rev+ (n=3093)
USA pts in category (%) 22.1 20.4 41.3
Mean age (years) 65.5 66.7 62.6
+ve cardiac markers (init/pk; 
%)
63.0 57.7 76.5
Pts receiving PCI/CABG (%) 35.3/6.2 *2.6/0.5 50.5/10.9
Discharge-transfer to acute 
facility (%)
4.3 19.5 6.0
Total length of stay, days, 
mean (med) [95%CI]
8.9 (7.0) [8.8, 9.0] 8.5 (7.0) [8.3, 
8.7]
9.8 (7.0) [9.5, 
10.0]
Total index hospital costs, 
mean (med)[95%CI]
Europe
5595 
(4671)[5557, 
5633]
4267 
(3752)[4224, 
4310]
6732 (5428)[6628, 
6836]
US 6712 (5171) 
[6665, 6759]
3953 (3299) 
[3910, 3996]
8572 (7878) 
[8450, 8694]
Note all comparisons (1 vs 2) & (1 vs 3) P<0.001 except Wilcoxon for length of stay
*Some Rev- centers were linked to Rev+ centers as one combined trust
